» Articles » PMID: 38177459

Multiregion Sampling of De Novo Metastatic Prostate Cancer Reveals Complex Polyclonality and Augments Clinical Genotyping

Abstract

De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical intervention in 43 de novo metastatic prostate cancers to assess somatic genotypes across 607 synchronous primary and metastatic tissue regions plus circulating tumor DNA. Intra-prostate heterogeneity was pervasive and impacted clinically relevant genes, resulting in discordant genotypes between select primary restricted regions and synchronous metastases. Additional complexity was driven by polyclonal metastatic seeding from phylogenetically related primary populations. When simulating clinical practice relying on a single tissue region, genomic heterogeneity plus variable tumor fraction across samples caused inaccurate genotyping of dominant disease; however, pooling extracted DNA from multiple biopsy cores before sequencing can rescue misassigned somatic genotypes. Our results define the relationship between synchronous treatment-sensitive primary and metastatic lesions in men with de novo metastatic prostate cancer and provide a framework for implementing genomics-guided patient management.

Citing Articles

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.

Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P Cell Rep Med. 2025; 6(2):101937.

PMID: 39914385 PMC: 11866514. DOI: 10.1016/j.xcrm.2025.101937.


An Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer.

Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T Cancers (Basel). 2025; 17(2).

PMID: 39857987 PMC: 11763793. DOI: 10.3390/cancers17020205.


Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer.

Rhinehart D, Lai J, Sanin D, Vakkala V, Mendes A, Bailey C NPJ Precis Oncol. 2024; 8(1):275.

PMID: 39623053 PMC: 11612198. DOI: 10.1038/s41698-024-00773-w.


Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.

Sharifi N, Diaz R, Lin H, Roberts E, Horvath L, Martin A J Clin Invest. 2024; 134(18).

PMID: 39286977 PMC: 11405037. DOI: 10.1172/JCI183583.


Impact of loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Slootbeek P, Luna-Velez M, Prive B, van der Doelen M, Kloots I, Pamidimarri Naga S Theranostics. 2024; 14(12):4555-4569.

PMID: 39239510 PMC: 11373632. DOI: 10.7150/thno.96322.


References
1.
Helgstrand J, Roder M, Klemann N, Toft B, Lichtensztajn D, Brooks J . Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer. 2018; 124(14):2931-2938. DOI: 10.1002/cncr.31384. View

2.
Hamid A, Sayegh N, Tombal B, Hussain M, Sweeney C, Graff J . Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. Am Soc Clin Oncol Educ Book. 2023; 43:e390166. DOI: 10.1200/EDBK_390166. View

3.
Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

4.
Gravis G, Boher J, Chen Y, Liu G, Fizazi K, Carducci M . Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018; 73(6):847-855. PMC: 6010352. DOI: 10.1016/j.eururo.2018.02.001. View

5.
Vapiwala N, Hofman M, Murphy D, Williams S, Sweeney C . Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. J Clin Oncol. 2019; 37(10):765-769. DOI: 10.1200/JCO.18.01927. View